Zimmer Biomet (ZBH) PT Lowered to $137 at BMO Capital; 'Making Very Early Progress, Resetting the Bar'
BMO Capital lowered its price target on Zimmer Biomet (NYSE: ZBH) to $137.00 (from $144.00) while maintaining a Outperform rating.
BMO Capital lowered its price target on Zimmer Biomet (NYSE: ZBH) to $137.00 (from $144.00) while maintaining a Outperform rating.